PillRight US Source Policy
Last reviewed: June 12, 2026
Source-first rule
The U.S. version should show source-linked summaries and clear interpretation boundaries. It should not publish copied label pages, unsourced safety claims, or NDC-only approval assumptions.
Official sources and usage
DailyMed
U.S. National Library of Medicine
Primary source for Structured Product Labeling sections, label dates, warnings, indications, dosage, and patient medication guides.
Open official sourceRxNorm
U.S. National Library of Medicine
Concept identity layer for ingredients, clinical drugs, brand names, and related RxCUI mappings.
Open official sourceDrugs@FDA
U.S. Food and Drug Administration
FDA approval and application context for approved prescription and over-the-counter drug products.
Open official sourceOrange Book
U.S. Food and Drug Administration
Therapeutic equivalence and application data for products listed in the FDA Orange Book.
Open official sourceopenFDA drug labeling
U.S. Food and Drug Administration
Search and retrieval layer for selected labeling fields. Used as a convenience API, not as the only source of truth.
Open official sourceopenFDA NDC directory
U.S. Food and Drug Administration
Listing and packaging context for NDC records. NDC listing is not treated as proof of FDA approval.
Open official sourceImportant interpretation boundaries
- DailyMed labeling can include marketed products and label revisions, but page summaries must still cite the specific label used.
- RxNorm helps identify drug concepts, but it does not by itself decide product approval, availability, or clinical suitability.
- Drugs@FDA and Orange Book data should be used for approval and therapeutic-equivalence context when applicable.
- NDC listing and packaging records are not treated as proof that a product is FDA approved.
- Label summaries must tell users to confirm decisions with a clinician, pharmacist, official label, or emergency service when appropriate.